234 related articles for article (PubMed ID: 16808884)
1. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA.
Zhang Z; Tang LL; Zhan RY; Tong Y; Yao HP; Du LA
J Zhejiang Univ Sci; 2004 Oct; 5(10):1298-303. PubMed ID: 15362204
[TBL] [Abstract][Full Text] [Related]
3. [Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas].
Yu JB; Feng ZX; Zhan RY
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 36(6):592-7. PubMed ID: 18067234
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
5. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
8. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas.
Ni HT; Spellman SR; Jean WC; Hall WA; Low WC
J Neurooncol; 2001 Jan; 51(1):1-9. PubMed ID: 11349874
[TBL] [Abstract][Full Text] [Related]
9. Cell therapies in neuro-oncology.
Pellegatta S; Finocchiaro G
Neurol Sci; 2005 May; 26 Suppl 1():S43-5. PubMed ID: 15883693
[TBL] [Abstract][Full Text] [Related]
10. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ
Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066
[TBL] [Abstract][Full Text] [Related]
11. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
12. DCVax-Brain and DC vaccines in the treatment of GBM.
Wheeler CJ; Black KL
Expert Opin Investig Drugs; 2009 Apr; 18(4):509-19. PubMed ID: 19335279
[TBL] [Abstract][Full Text] [Related]
13. DCVax®-L--developed by Northwest Biotherapeutics.
Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
[TBL] [Abstract][Full Text] [Related]
14. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
[TBL] [Abstract][Full Text] [Related]
15. Novel mechanisms and approaches in immunotherapy for brain tumors.
Finocchiaro G; Pellegatta S
Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
[TBL] [Abstract][Full Text] [Related]
16. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell immunotherapy for glioblastoma.
Polyzoidis S; Ashkan K
Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell immunotherapy for brain tumors.
Antonios JP; Everson RG; Liau LM
J Neurooncol; 2015 Jul; 123(3):425-32. PubMed ID: 26037466
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
20. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
